Monograph Details
|
|
Infections & Infestations
> Viral infections
|
|
VIRAZOLE |
| Manufacturer |
|
Valeant Pharmaceuticals, Inc |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Nucleoside analogue. |
| Generic Name |
|
Ribavirin 6g/vial; pwd for reconstitution and aerosol inhalation. |
| Indications |
|
Severe lower respiratory infections due to respiratory syncytial virus in hospitalized infants and young children. |
| Children |
|
Begin treatment preferably within first 3 days of infection. 20mg/mL as starting solution in drug reservoir for continuous aerosol administration for 12–18 hours per day for 3–7 days. |
| Adults |
|
Not recommended. |
| Contraindications |
|
Pregnancy (Cat.X). |
| Precautions |
|
See literature. Monitor respiratory function, fluid status. Discontinue if pulmonary function deteriorates. Drug may precipitate in mechanical ventilator, causing dysfunction. Avoid unnecessary occupational exposure. Nursing mothers. |
| Interactions |
|
Monitor digitalis. |
| Adverse Reactions |
|
Pulmonary function deterioration, bronchospasm, pulmonary edema, hypoventilation, bacterial pneumonia, pneumothorax, apnea, ventilator dependence, atelectasis, cardiac arrest, hypotension, reticulocytosis, hemolytic anemia, rash, conjunctivitis. |
| How Supplied |
|
Vials—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
